Leaders bring more than 45 years of sales and marketing leadership to the company

REDMOND, Wash.–(BUSINESS WIRE)–EndoGastric® Solutions, Inc. (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today the addition of two senior executives to its leadership team: Martin Reid, Vice President of Sales, and Ted Stephens, Vice President of Marketing and Professional Education.

In their respective roles, Reid and Stephens will focus on meeting increased commercial demand of the Transoral Incisionless Fundoplication (TIF®) 2.0 procedure using EsophyX® technology, a minimally-invasive procedure for the treatment of GERD. An estimated 1 in 5 Americans suffer from GERD, or weekly heartburn and/or regurgitation.1

“With EndoGastric Solutions on a path of rapid growth, the addition of these highly experienced commercial leaders is a critical component of our ongoing commercial strategy,” said Skip Baldino, President and CEO, EndoGastric Solutions. “Both Ted and Martin bring a deep understanding of the health care industry and are committed to making the TIF procedure a core component of physicians’ treatment approach to GERD patients across the country and abroad.”

Martin Reid, Vice President of Sales
With more than 25 years of experience in health care, Reid has held a variety of positions in sales, leadership and business development throughout his career. He most recently served as Area Vice President at Olympus Corporation of the Americas. Prior to that, Reid has served as National Sales Manager at Johnson & Johnson, Sedasys; Director of Sales at Xenex Disinfection Services; Regional Sales Manager at Given Imaging (acquired by Medtronic GI Solutions); President of his own medical device consulting practice, Reid Agency; National Sales Manager at NeoPath, Inc.; and Regional Sales Manager at Boston Scientific Corporation. He began his career with Johnson & Johnson in the Ethicon division after graduating from Whitworth University with a Bachelor of Arts degree in business management.

Ted Stephens, Vice President of Marketing and Professional Education
Stephens brings over 20 years of diverse commercial leadership across global markets in the medical device industry, with extensive knowledge in both minimally-invasive surgery and therapeutic gastrointestinal markets. Stephens most recently served as Director of Marketing for NOVADAQ Technologies. Prior to that he was the Vice President of Global Marketing at Apollo Endosurgery where he led a global team to develop and execute marketing strategies for a portfolio of surgical and therapeutic GI products. He also spent 16 years at Ethicon Endo-Surgery with various positions in engineering, sales, sales leadership and marketing. Stephens earned his Master’s degree in Business Administration from Xavier University and a Bachelor of Science in engineering from Michigan State University.

For more information on EndoGastric Solutions and to find additional career opportunities, visit www.endogastricsolutions.com.

About Current Procedural Terminology (CPT®)
CPT codes are a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services. The coding serves as an effective way to provide communication among healthcare providers, patients and third parties. CPT is registered trademark of the American Medical Association.

The Federal Register posts coding and payment information specific to the CPT code, allowing patients to receive access to treatment more easily for GERD. Physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty and APC 5331 Complex GI Procedures for TIF® procedures.

NP02450-20A/-01F
Share

About GERD
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disease that affects nearly 20 percent of the U.S. population. It is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. In the United States (U.S.), GERD is the most common gastrointestinal-related diagnosis physicians make during clinical visits. Some patients may have mild or moderate symptoms of GERD, while others have more severe manifestations causing chronic heartburn, asthma, chronic cough, and hoarse voice or chest pain. Left untreated, GERD can develop into a pre-cancerous condition called Barrett’s esophagus, which is a precursor for esophageal cancer. The first treatment recommendation for patients with GERD is to make lifestyle changes (e.g., diet, scheduled eating times and sleeping positions). Proton pump inhibitor (PPI) medications are commonly used to treat GERD, but there are a variety of health complications associated with long-term dependency on PPIs, and more than 10 million Americans are refractory to PPI therapy and may opt for surgery.

About Transoral Incisionless Fundoplication (TIF® 2.0 procedure) for Reflux
The TIF 2.0 procedure enables an incisionless approach to fundoplication in which a device is inserted through the mouth, down the esophagus and into the upper portion of the stomach. This approach offers patients looking for an alternative to traditional surgery an effective treatment option to correct the underlying cause of GERD. Based on clinical studies, most patients stopped using daily medications to control their symptoms and had their esophageal inflammation (esophagitis) eliminated up to five years after the TIF 2.0 procedure. Additionally, clinical results have demonstrated that concomitant laparoscopic hiatal hernia repair (LHHR) immediately followed by TIF 2.0 procedure is safe and effective in patients requiring repair of both anatomical defects.

Over 25,000 TIF procedures have been performed worldwide. More than 140 peer-reviewed papers have consistently documented the sustained improved clinical outcomes and exemplary safety profile the TIF procedure provides to patients suffering from GERD. For more information, please visit www.GERDHelp.com.

About Reimbursement
With the support of clinical societies, commercial and federal insurance providers, representing more than 100 million lives, have recognized the value of the TIF 2.0 procedure through recently expanded coverage policies. The TIF 2.0 procedure is a covered benefit for all Medicare beneficiaries across the country.

For the TIF 2.0 procedure, physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty. CPT is a registered trademark of the American Medical Association.

About EsophyX® Technology
The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids from refluxing back into the esophagus. The device is inserted through the patient’s mouth with direct visual guidance from an endoscope, and enables creation of a 3 cm, 270° esophagogastric fundoplication. The U.S. Food and Drug Administration cleared the original EsophyX device in 2007. The evolving technology, including the latest iteration EsophyX Z+, launched in 2017, enables surgeons and gastroenterologists to use a wide selection of endoscopes to treat the underlying anatomical cause of GERD.

Indications
The EsophyX device, with SerosaFuse® fasteners and accessories, is indicated for use in transoral tissue approximation, full thickness plication and ligation in the gastrointestinal tract. It is indicated for the treatment of symptomatic chronic GERD in patients who require and respond to pharmacological therapy. The device is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia ≤ 2 cm in size in patients with symptomatic chronic GERD. Patients with hiatal hernias larger than 2 cm may be included, when a laparoscopic hiatal hernia repair reduces the hernia to 2 cm or less.

About EndoGastric Solutions®
Based in Redmond, Washington, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of GERD. EGS has combined the most advanced concepts in gastroenterology and surgery to develop products and procedures to treat gastrointestinal diseases, including the TIF 2.0 procedure—a minimally invasive solution that addresses a significant unmet clinical need. Join the conversation on Twitter: @GERDHelp Facebook: GERDHelp and LinkedIn: EndoGastric Solutions.

# # #

Contact:
Ted Stephens
EndoGastric Solutions, Inc.
Phone: +1 513-312-9161
tstephens@endogastricsolutions.com

Erich Sandoval
Lazar Partners
Phone: +1 917-497-2867
esandoval@lazarpartners.com